Qiagen Stock Gains Momentum Following FDA Clearance for New Diagnostics Market

The U.S. Food and Drug Administration's recent clearance of Qiagen's diagnostic technology opens a new market segment, prompting investor optimism about the company's potential stock growth and competitive positioning in the healthcare sector.